Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Azd7986
2. Ins-1007
3. Ins1007
4. N-(1-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide
1. Azd7986
2. 1802148-05-5
3. Ins1007
4. (s)-n-((s)-1-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide
5. Brensocatib [usan]
6. Azd 7986
7. Azd-7986
8. Ins-1007
9. 25cg88l0bb
10. Chembl3900409
11. (2s)-n-[(1s)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide
12. (s)-n-((s)-1-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo-(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide
13. 1,4-oxazepine-2-carboxamide, N-((1s)-1-cyano-2-(4-(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)phenyl)ethyl)hexahydro-, (2s)-
14. Ins 1007
15. Brensocatib [inn]
16. Unii-25cg88l0bb
17. Brensocatib [who-dd]
18. Gtpl9412
19. Schembl16932317
20. Ex-a1866
21. Bdbm50195235
22. Pz1130
23. Who 11097
24. Ac-36222
25. As-84225
26. Bb177302
27. Hy-101056
28. Cs-0020766
29. J3.556.230c
30. A17095
31. D84088
32. A937370
33. (2s)-n-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
34. (s)-3-[4-(2-oxo-3-methyl-2,3-dihydrobenzoxazole-5-yl)phenyl]-2-[(hexahydro-1,4-oxazepine-2alpha-yl)carbonylamino]propanenitrile
Molecular Weight | 420.5 g/mol |
---|---|
Molecular Formula | C23H24N4O4 |
XLogP3 | 2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 5 |
Exact Mass | 420.17975526 g/mol |
Monoisotopic Mass | 420.17975526 g/mol |
Topological Polar Surface Area | 104 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 699 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of non-cystic fibrosis bronchiectasis
ABOUT THIS PAGE
52
PharmaCompass offers a list of Brensocatib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Brensocatib manufacturer or Brensocatib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Brensocatib manufacturer or Brensocatib supplier.
PharmaCompass also assists you with knowing the Brensocatib API Price utilized in the formulation of products. Brensocatib API Price is not always fixed or binding as the Brensocatib Price is obtained through a variety of data sources. The Brensocatib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A INS 1007 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of INS 1007, including repackagers and relabelers. The FDA regulates INS 1007 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. INS 1007 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A INS 1007 supplier is an individual or a company that provides INS 1007 active pharmaceutical ingredient (API) or INS 1007 finished formulations upon request. The INS 1007 suppliers may include INS 1007 API manufacturers, exporters, distributors and traders.
INS 1007 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of INS 1007 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right INS 1007 GMP manufacturer or INS 1007 GMP API supplier for your needs.
A INS 1007 CoA (Certificate of Analysis) is a formal document that attests to INS 1007's compliance with INS 1007 specifications and serves as a tool for batch-level quality control.
INS 1007 CoA mostly includes findings from lab analyses of a specific batch. For each INS 1007 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
INS 1007 may be tested according to a variety of international standards, such as European Pharmacopoeia (INS 1007 EP), INS 1007 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (INS 1007 USP).